Clinical Trial Update: EarLy Treatment Response in nEoVascular Macular Degeneration With Eylea 8mg: ELEV8 A Prospective Observational Open Label Study Investigating the Fluid Dynamics During Early Response to Aflibercept 8mg in Patients With Exudative Age-related Macular Degeneration (AMD).

View source ↗

Summary

A prospective, open-label observational study evaluating fluid dynamics during early response to aflibercept 8 mg (Eylea) in patients with exudative age-related…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• EYLEA (Aflibercept)

Snippet

Sponsor: Insel Gruppe AG, University Hospital Bern | Conditions: Age-Related Macular Degeneration (AMD) | Status: RECRUITING